BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 38551031)

  • 1. Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk.
    Pike MC; Spicer DV; Dahmoush L; Press MF
    Epidemiol Rev; 1993; 15(1):17-35. PubMed ID: 8405201
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lobular breast cancer: incidence and genetic and non-genetic risk factors.
    Dossus L; Benusiglio PR
    Breast Cancer Res; 2015 Mar; 17():37. PubMed ID: 25848941
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is There a Special Role for Ovarian Hormones in the Pathogenesis of Lobular Carcinoma?
    Flaherty RL; Sflomos G; Brisken C
    Endocrinology; 2024 Mar; 165(5):. PubMed ID: 38551031
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relation of regimens of combined hormone replacement therapy to lobular, ductal, and other histologic types of breast carcinoma.
    Daling JR; Malone KE; Doody DR; Voigt LF; Bernstein L; Coates RJ; Marchbanks PA; Norman SA; Weiss LK; Ursin G; Berlin JA; Burkman RT; Deapen D; Folger SG; McDonald JA; Simon MS; Strom BL; Wingo PA; Spirtas R
    Cancer; 2002 Dec; 95(12):2455-64. PubMed ID: 12467057
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between long durations and different regimens of hormone therapy and risk of breast cancer.
    Li CI; Malone KE; Porter PL; Weiss NS; Tang MT; Cushing-Haugen KL; Daling JR
    JAMA; 2003 Jun; 289(24):3254-63. PubMed ID: 12824206
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Menopausal hormone therapy and other breast cancer risk factors in relation to the risk of different histological subtypes of breast cancer: a case-control study.
    Rosenberg LU; Magnusson C; Lindström E; Wedrén S; Hall P; Dickman PW
    Breast Cancer Res; 2006; 8(1):R11. PubMed ID: 16507159
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Menopausal hormone therapy and risk of clinical breast cancer subtypes.
    Slanger TE; Chang-Claude JC; Obi N; Kropp S; Berger J; Vettorazzi E; Braendle W; Bastert G; Hentschel S; Flesch-Janys D
    Cancer Epidemiol Biomarkers Prev; 2009 Apr; 18(4):1188-96. PubMed ID: 19336542
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of different postmenopausal hormone therapies and risk of histology- and hormone receptor-defined invasive breast cancer.
    Fournier A; Fabre A; Mesrine S; Boutron-Ruault MC; Berrino F; Clavel-Chapelon F
    J Clin Oncol; 2008 Mar; 26(8):1260-8. PubMed ID: 18323549
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The clinical significance of oestrogen receptor expression in breast ductal carcinoma in situ.
    Miligy IM; Toss MS; Shiino S; Oni G; Syed BM; Khout H; Tan QT; Green AR; Macmillan RD; Robertson JFR; Rakha EA
    Br J Cancer; 2020 Nov; 123(10):1513-1520. PubMed ID: 32773767
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Invasive Lobular Breast Cancer as a Distinct Disease: Implications for Therapeutic Strategy.
    Luveta J; Parks RM; Heery DM; Cheung KL; Johnston SJ
    Oncol Ther; 2020 Jun; 8(1):1-11. PubMed ID: 32700069
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential Regulation and Targeting of Estrogen Receptor α Turnover in Invasive Lobular Breast Carcinoma.
    Sreekumar S; Levine KM; Sikora MJ; Chen J; Tasdemir N; Carter D; Dabbs DJ; Meier C; Basudan A; Boone D; McAuliffe PF; Jankowitz RC; Lee AV; Atkinson JM; Oesterreich S
    Endocrinology; 2020 Sep; 161(9):. PubMed ID: 32609836
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Levonorgestrel-releasing intrauterine system and breast cancer risk: A systematic review and meta-analysis.
    Conz L; Mota BS; Bahamondes L; Teixeira Dória M; Françoise Mauricette Derchain S; Rieira R; Sarian LO
    Acta Obstet Gynecol Scand; 2020 Aug; 99(8):970-982. PubMed ID: 31990981
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Do Body Mass Index and Breast Density Impact Cancer Risk Among Women with Lobular Carcinoma In Situ?
    Minami CA; Zabor EC; Gilbert E; Newman A; Park A; Jochelson MS; King TA; Pilewskie ML
    Ann Surg Oncol; 2020 Jun; 27(6):1844-1851. PubMed ID: 31898097
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence.
    Collaborative Group on Hormonal Factors in Breast Cancer
    Lancet; 2019 Sep; 394(10204):1159-1168. PubMed ID: 31474332
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reproductive risk factor associations with lobular and ductal carcinoma in the Carolina Breast Cancer Study.
    Williams LA; Nichols HB; Hoadley KA; Tse CK; Geradts J; Bell ME; Perou CM; Love MI; Olshan AF; Troester MA
    Cancer Causes Control; 2018 Jan; 29(1):25-32. PubMed ID: 29124544
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.